C J Reist
Overview
Explore the profile of C J Reist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
810
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OConnor C, Starling R, Hernandez A, Armstrong P, Dickstein K, Hasselblad V, et al.
N Engl J Med
. 2011 Jul;
365(1):32-43.
PMID: 21732835
Background: Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality...
2.
Foulon C, Reist C, Bigner D, Zalutsky M
Cancer Res
. 2000 Sep;
60(16):4453-60.
PMID: 10969792
The mutant epidermal growth factor receptor variant III (EGFRvIII) has been found on gliomas and other tumors but not on normal tissues, including those that express the wild-type receptor. Monoclonal...
3.
Kuan C, Reist C, Foulon C, Lorimer I, Archer G, Pegram C, et al.
Clin Cancer Res
. 1999 Jul;
5(6):1539-49.
PMID: 10389943
A single-chain antibody fragment, MR1(scFv), with specific binding to epidermal growth factor receptor-vIII (EGFRvIII), was produced, radiolabeled, and evaluated for biodistribution in human glioma-bearing athymic mice. The mutant receptor EGFRvIII...
4.
Reist C, Foulon C, Alston K, Bigner D, Zalutsky M
Nucl Med Biol
. 1999 Jun;
26(4):405-11.
PMID: 10382844
Monoclonal antibodies (MAbs) such as the anti-epidermal growth factor variant III (EGFRvIII) MAb L8A4 are rapidly internalized, which can lead to rapid loss of radioactivity from the tumor cell. The...
5.
Akabani G, Reist C, Cokgor I, Friedman A, Friedman H, Coleman R, et al.
J Nucl Med
. 1999 Apr;
40(4):631-8.
PMID: 10210222
Unlabelled: The objective of this study was to perform the dosimetry of 131I-labeled 81C6 monoclonal antibody (MAb) in patients with recurrent malignant brain tumors, treated by direct injections of MAb...
6.
Reist C, Bigner D, Zalutsky M
Clin Cancer Res
. 1998 Oct;
4(10):2495-502.
PMID: 9796983
The in vivo properties of radiolabeled chimeric monoclonal antibodies (mAbs) with human IgG1 and IgG3 constant regions generally are similar to those of their corresponding murine construct. In contrast, we...
7.
Wikstrand C, Reist C, Archer G, Zalutsky M, Bigner D
J Neurovirol
. 1998 May;
4(2):148-58.
PMID: 9584952
Any immunotherapeutic approach to cancer cell eradication is based upon the specific recognition of neoplastic cells and the sparing of surrounding normal tissue; perhaps nowhere is this distinction more important...
8.
Reist C, Batra S, Pegram C, Bigner D, Zalutsky M
Nucl Med Biol
. 1997 Nov;
24(7):639-47.
PMID: 9352535
The mutant version of the epidermal growth factor receptor EGFRvIII has been found on gliomas and other tumors, but not on normal tissues. Radioiodinated murine (mu) L8A4 monoclonal antibody (MAb)...
9.
Reist C, Archer G, Wikstrand C, Bigner D, Zalutsky M
Cancer Res
. 1997 Apr;
57(8):1510-5.
PMID: 9108453
Monoclonal antibody (mAb) L8A4, specific for the tumor-associated mutant epidermal growth factor receptor variant III (EGFRvII), is internalized and degraded after cell binding. Four paired-label experiments were performed in athymic...
10.
Moynihan K, ELION G, Pegram C, Reist C, Wellner D, Bigner D, et al.
Cancer Chemother Pharmacol
. 1997 Jan;
39(3):179-86.
PMID: 8996517
These studies evaluated the efficacy of sequential pretreatment with L-amino acid oxidase (LOX) and LOX antiserum in the modulation of melphalan activity against intracranial glioma in athymic nude mice. LOX...